These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8449606)

  • 1. Combined therapy with IL-6 and inactivated tumor cells suppresses metastasis in mice bearing 3LL lung carcinomas.
    Katz A; Shulman LM; Revel M; Feldman M; Eisenbach L
    Int J Cancer; 1993 Mar; 53(5):812-8. PubMed ID: 8449606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of B16 melanoma metastases by long-term low-dose interleukin-6 therapy.
    Katz A; Shulman LM; Porgador A; Revel M; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):98-109. PubMed ID: 8318501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells.
    Porgador A; Gansbacher B; Bannerji R; Tzehoval E; Gilboa E; Feldman M; Eisenbach L
    Int J Cancer; 1993 Feb; 53(3):471-7. PubMed ID: 8428800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapy via gene therapy: comparison of the effects of tumor cells transduced with the interleukin-2, interleukin-6, or interferon-gamma genes.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    J Immunother Emphasis Tumor Immunol; 1993 Oct; 14(3):191-201. PubMed ID: 7905286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells.
    Eisenbach L; Hollander N; Greenfeld L; Yakor H; Segal S; Feldman M
    Int J Cancer; 1984 Oct; 34(4):567-73. PubMed ID: 6490207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells.
    Porgador A; Tzehoval E; Katz A; Vadai E; Revel M; Feldman M; Eisenbach L
    Cancer Res; 1992 Jul; 52(13):3679-86. PubMed ID: 1617640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo effects of recombinant human interleukin 6, alone or in combination with local irradiation, on tumor growth in Lewis lung carcinoma-bearing mice.
    Lu L; Shen RN; Broxmeyer HE
    Int J Cell Cloning; 1991 Sep; 9(5):511-20. PubMed ID: 1955739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
    Fukuta K; Sone S; Kitahara M; Okada M; Ogura T
    Jpn J Cancer Res; 1989 Jun; 80(6):562-7. PubMed ID: 2503476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of two H-2K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells.
    Mandelboim O; Vadai E; Feldman M; Eisenbach L
    Gene Ther; 1995 Dec; 2(10):757-65. PubMed ID: 8750016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of growth and metastases in mice by immunization with cholesterol hemisuccinate-enriched tumor cells.
    Skornick Y; Gorelik E; Klausner J; Shinitzky M; Sindelar WF
    Cancer Lett; 1984 Dec; 25(2):153-61. PubMed ID: 6509434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of established pancreatic cancers following specific active immunotherapy with interleukin-2 gene-transduced tumor cells.
    Clary BM; Coveney EC; Philip R; Blazer DG; Morse M; Gilboa E; Lyerly HK
    Cancer Gene Ther; 1997; 4(2):97-104. PubMed ID: 9080118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adoptive immunotherapy of microscopic and advanced visceral metastases with in vitro sensitized lymphoid cells from mice bearing progressive tumors.
    Chou T; Bertera S; Chang AE; Shu S
    J Immunol; 1988 Sep; 141(5):1775-81. PubMed ID: 3261761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
    Nomi S; Naito K; Kahan BD; Pellis NR
    Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Z-100, an immunomodulator extracted from human type tubercle bacilli, on the pulmonary metastases of Lewis lung carcinoma in attempt to regulate suppressor T cells and suppressor factor, IL-4.
    Emori Y; Sasaki H; Hayashi Y; Nomoto K
    Biotherapy; 1996; 9(4):249-56. PubMed ID: 9012544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of local interleukin-2 treatment on spontaneous tumours of different immunogenic strength.
    Fiszer-Maliszewska L; Den Otter W; Mordarski M
    Cancer Immunol Immunother; 1999 Feb; 47(6):307-14. PubMed ID: 10203060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-tumor effects of interleukin-2 and interleukin-1 in mice transplanted with different syngeneic tumors.
    Belardelli F; Ciolli V; Testa U; Montesoro E; Bulgarini D; Proietti E; Borghi P; Sestili P; Locardi C; Peschle C
    Int J Cancer; 1989 Dec; 44(6):1108-16. PubMed ID: 2606579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of murine tumor class I major histocompatibility complex expression on antitumor activity of tumor-infiltrating lymphocytes.
    Weber JS; Rosenberg SA
    J Natl Cancer Inst; 1990 May; 82(9):755-61. PubMed ID: 2109092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.